Ahead of Alzheimer’s meeting, researchers seize on signs of progress
By Bill Berkrot and Ransdell Pierson NEW YORK (Reuters) – After decades of Alzheimer’s research that led to dead ends, including 123 drugs that failed, top researchers in the field say they are far more confident now of producing an effective treatment. New experimental drugs from Eli Lilly and Co and Biogen have shown promise in slowing down the progression of the mind-wasting disease, attracting the attention of investors and patients. “The recurring platitude, which has been going on forever is ‘gee we’re about five years away from a really effective treatment,'” said Steven Ferris, who directs the Alzheimer’s clinical trials program at NYU Langone Medical Center in New York.